MindMed has initiated a Phase 1 investigator-initiated trial led by collaborator Professor Dr Matthias Liechti at University Hospital Basel (UHB).
atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial...
Optimi Health Corp.
The clinical trial will be testing the safety and tolerability of MDMA-assisted therapy for patients living with treatment-resistant post-traumatic stress disorder (PTSD).
MAPS PBC is entering into a collaboration that aims to bring its novel therapy for PTSD closer to regulatory evaluation.
The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) has confirmed it has now fully enroled its Phase III trial of MDMA-assisted therapy for PTSD.
Delic Holdings Corp subsidiary, Delic Labs, has received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on psychedelic and...
The trial MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has advanced to the next implementation phase.
Follow-up data from a Phase III clinical trial shows that MDMA therapy could hold promise for millions suffering from the condition.
Historically dubbed the “love drug” for its ability to induce sensual feelings and pro-social behaviour, MDMA is now being researched for a number of social and...